1,981 reports of this reaction
1.5% of all SILDENAFIL reports
#16 most reported adverse reaction
PULMONARY ARTERIAL HYPERTENSION is the #16 most commonly reported adverse reaction for SILDENAFIL, manufactured by ANI Pharmaceuticals, Inc.. There are 1,981 FDA adverse event reports linking SILDENAFIL to PULMONARY ARTERIAL HYPERTENSION. This represents approximately 1.5% of all 132,502 adverse event reports for this drug.
SILDENAFIL has an overall safety score of 85 out of 100. Patients taking SILDENAFIL who experience pulmonary arterial hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY ARTERIAL HYPERTENSION is a less commonly reported adverse event for SILDENAFIL, but still significant enough to appear in the safety profile.
In addition to pulmonary arterial hypertension, the following adverse reactions have been reported for SILDENAFIL:
The following drugs have also been linked to pulmonary arterial hypertension in FDA adverse event reports:
PULMONARY ARTERIAL HYPERTENSION has been reported as an adverse event in 1,981 FDA reports for SILDENAFIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY ARTERIAL HYPERTENSION accounts for approximately 1.5% of all adverse event reports for SILDENAFIL, making it a notable side effect.
If you experience pulmonary arterial hypertension while taking SILDENAFIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.